Current Value
$0.431 Year Return
Current Value
$0.431 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RIVN | <0.01% | $17.54B | +51.04% | 0.00% |
ECL | -0.01% | $72.55B | +10.01% | 0.95% |
AMG | 0.01% | $5.14B | +13.83% | 0.02% |
CFLT | -0.01% | $7.73B | -27.94% | 0.00% |
RGR | 0.02% | $615.68M | -13.69% | 1.89% |
GFS | 0.02% | $21.86B | -27.02% | 0.00% |
HTLD | 0.03% | $717.98M | -20.73% | 0.88% |
PSQH | 0.03% | $89.26M | -49.87% | 0.00% |
ZIP | 0.04% | $493.31M | -46.42% | 0.00% |
PARR | 0.05% | $1.06B | -28.69% | 0.00% |
LEVI | -0.05% | $6.92B | -21.13% | 2.96% |
BUD | -0.05% | $118.39B | +1.58% | 1.56% |
GUG | -0.06% | - | - | 9.19% |
VLO | 0.07% | $42.40B | -14.59% | 3.21% |
EWCZ | -0.07% | $238.18M | -50.98% | 0.00% |
TLYS | -0.08% | $23.87M | -87.29% | 0.00% |
SATS | 0.08% | $6.58B | +33.84% | 0.00% |
ALGT | -0.08% | $1.01B | +0.91% | 0.00% |
WOOF | 0.09% | $879.15M | +28.86% | 0.00% |
BFAM | 0.09% | $7.00B | +8.57% | 0.00% |
Yahoo
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the we
Yahoo
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today prov
Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Yahoo
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers. “Dosing the first patient in the LNCB74 Phase 1 study is a significant milestone for NextC
Yahoo
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem BiosciencesBELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of
Yahoo
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website a
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTC | 36.09% | $4.48B | 0.15% |
EZET | 25.69% | $34.72M | 0% |
QETH | 25.67% | $22.91M | 0.25% |
ETH | 25.65% | $1.13B | 0% |
ETHV | 25.56% | $123.08M | 0% |
ETHW | 25.50% | $250.22M | 0% |
FETH | 25.47% | $1.08B | 0.25% |
CETH | 25.45% | $24.05M | 0% |
ETHA | 25.37% | $3.38B | 0.25% |
EETH | 21.59% | $67.45M | 0.95% |
GNOM | 20.57% | $40.65M | 0.5% |
BTF | 20.35% | $35.22M | 1.25% |
OVT | 19.59% | $50.87M | 0.8% |
PTH | 19.30% | $96.56M | 0.6% |
ETHE | 18.76% | $3.04B | 2.5% |
XBI | 18.54% | $4.85B | 0.35% |
MORT | 17.33% | $291.02M | 0.43% |
IWC | 17.28% | $766.88M | 0.6% |
CPRJ | 17.24% | $48.43M | 0.69% |
JPLD | 17.21% | $1.19B | 0.24% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CMDY | -<0.01% | $258.39M | 0.28% |
IVOL | -0.01% | $353.94M | 1.02% |
ICLO | -0.01% | $305.65M | 0.19% |
REZ | -0.01% | $801.88M | 0.48% |
FTXG | 0.02% | $34.98M | 0.6% |
JUCY | 0.03% | $297.77M | 0.6% |
XAR | 0.12% | $2.97B | 0.35% |
VRP | -0.13% | $2.05B | 0.5% |
KRBN | 0.15% | $160.09M | 0.85% |
HEZU | -0.16% | $711.39M | 0.53% |
CLOZ | 0.17% | $678.40M | 0.5% |
PWZ | 0.20% | $671.52M | 0.28% |
FEZ | -0.24% | $4.55B | 0.29% |
EWG | -0.26% | $2.50B | 0.5% |
FXI | 0.30% | $6.09B | 0.74% |
JBBB | -0.30% | $1.29B | 0.48% |
BCD | 0.41% | $269.40M | 0.3% |
ESPO | -0.42% | $338.45M | 0.56% |
IAK | 0.42% | $788.85M | 0.39% |
EWL | 0.42% | $1.21B | 0.5% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -12.31% | $109.64M | 0.85% |
BTAL | -11.11% | $361.41M | 1.43% |
HIGH | -10.12% | $188.11M | 0.52% |
TAIL | -9.92% | $140.49M | 0.59% |
SHLD | -9.14% | $1.87B | 0.5% |
SGOL | -8.75% | $5.06B | 0.17% |
GLDM | -8.74% | $14.42B | 0.1% |
GLD | -8.67% | $96.70B | 0.4% |
IAU | -8.59% | $45.68B | 0.25% |
AAAU | -8.48% | $1.47B | 0.18% |
BAR | -8.39% | $1.10B | 0.1749% |
OUNZ | -8.27% | $1.64B | 0.25% |
WEAT | -7.88% | $115.83M | 0.28% |
IYK | -7.78% | $1.48B | 0.4% |
CCOR | -7.74% | $59.79M | 1.18% |
CORN | -7.38% | $49.57M | 0.2% |
FXY | -7.19% | $838.61M | 0.4% |
FTSD | -6.65% | $212.46M | 0.25% |
KXI | -6.55% | $822.83M | 0.41% |
SOYB | -6.24% | $25.54M | 0.22% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NOC | -18.01% | $67.51B | -0.35% | 1.76% |
GFL | -15.65% | $17.98B | +53.65% | 0.12% |
KMB | -15.36% | $45.57B | +1.99% | 3.58% |
LITB | -15.27% | $21.28M | -72.45% | 0.00% |
ERIE | -13.48% | $17.14B | -7.12% | 1.44% |
PG | -13.18% | $380.78B | -3.25% | 2.51% |
CTLP | -13.13% | $615.88M | +23.25% | 0.00% |
FMTO | -12.85% | $45.74M | -99.96% | 0.00% |
GFI | -12.64% | $18.61B | +31.67% | 2.75% |
CME | -11.92% | $98.74B | +28.80% | 3.84% |
DCGO | -11.67% | $138.75M | -56.25% | 0.00% |
KO | -11.58% | $308.23B | +13.09% | 2.75% |
IOT | -11.56% | $26.72B | +15.53% | 0.00% |
QGEN | -11.40% | $9.13B | -10.71% | 0.00% |
ARLP | -11.39% | $3.42B | +17.02% | 10.52% |
GME | -11.22% | $12.81B | +3.47% | 0.00% |
KDP | -10.93% | $45.55B | -1.76% | 2.70% |
AJG | -10.90% | $86.63B | +32.39% | 0.72% |
SVV | -10.44% | $1.52B | -27.81% | 0.00% |
CHD | -10.43% | $23.29B | -11.36% | 1.23% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ACET | 34.30% | $52.77M | -59.36% | 0.00% |
CHMI | 28.09% | $100.26M | -16.12% | 19.35% |
SRPT | 27.69% | $3.47B | -73.43% | 0.00% |
ELVN | 23.53% | $874.36M | -25.16% | 0.00% |
ENTA | 23.48% | $114.56M | -58.88% | 0.00% |
GBIO | 22.46% | $25.18M | -90.04% | 0.00% |
RNA | 22.41% | $3.49B | +0.87% | 0.00% |
IMRN | 22.40% | $9.97M | -25.82% | 0.00% |
ITOS | 22.08% | $305.04M | -55.47% | 0.00% |
OLO | 22.01% | $1.54B | +86.64% | 0.00% |
NNOX | 21.91% | $347.50M | -44.56% | 0.00% |
ARR | 21.87% | $1.37B | -12.75% | 17.21% |
SDGR | 21.75% | $1.71B | +2.01% | 0.00% |
PRTA | 21.70% | $361.45M | -71.29% | 0.00% |
DX | 21.64% | $1.35B | -0.08% | 13.67% |
GREE | 21.63% | $15.12M | -58.87% | 0.00% |
ALEC | 21.60% | $110.49M | -79.87% | 0.00% |
TU | 21.39% | $23.77B | -4.62% | 7.19% |
ORC | 21.17% | $762.71M | -17.44% | 20.07% |
BTCT | 21.10% | $25.35M | +93.08% | 0.00% |